Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Brian Curran Healy, Ph.D.

Co-Author

This page shows the publications co-authored by Brian Healy and Samia Khoury.
Connection Strength

1.238
  1. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler. 2014 Apr; 20(4):438-44.
    View in: PubMed
    Score: 0.146
  2. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol. 2010 Sep; 67(9):1055-61.
    View in: PubMed
    Score: 0.118
  3. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17; 75(7):634-40.
    View in: PubMed
    Score: 0.118
  4. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.109
  5. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009 Jun 02; 72(22):1922-30.
    View in: PubMed
    Score: 0.109
  6. Daclizumab in treatment of multiple sclerosis patients. Mult Scler. 2009 Feb; 15(2):272-4.
    View in: PubMed
    Score: 0.106
  7. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology. 2008 Sep 16; 71(12):917-24.
    View in: PubMed
    Score: 0.103
  8. Identification of MS-specific serum miRNAs in an international multicenter study. Neurol Neuroimmunol Neuroinflamm. 2018 Sep; 5(5):e491.
    View in: PubMed
    Score: 0.051
  9. Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurol. 2013 Nov 11; 13:172.
    View in: PubMed
    Score: 0.037
  10. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013 Nov 26; 81(22):1891-9.
    View in: PubMed
    Score: 0.037
  11. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013 Jun; 73(6):729-40.
    View in: PubMed
    Score: 0.036
  12. No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurol. 2013 Jul 03; 13:73.
    View in: PubMed
    Score: 0.036
  13. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.032
  14. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2011 Apr; 21(2):e50-6.
    View in: PubMed
    Score: 0.031
  15. One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 Oct; 82(10):1125-31.
    View in: PubMed
    Score: 0.031
  16. HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes Immun. 2011 Apr; 12(3):183-90.
    View in: PubMed
    Score: 0.030
  17. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol. 2011 Apr; 233(1-2):168-74.
    View in: PubMed
    Score: 0.030
  18. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009 Jan; 19(1):3-8.
    View in: PubMed
    Score: 0.026
  19. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol. 2008 Nov; 65(11):1449-53.
    View in: PubMed
    Score: 0.026
  20. Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis. AJNR Am J Neuroradiol. 2008 Sep; 29(8):1465-70.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.